CC
SEEL

Capital Counsel’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Capital Counsel’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3
Closed -$9K – 63
2020
Q3 		$9K Buy
+3
New +$10.8K ﹤0.01% 61

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital Counsel's SEEL Position: Q4 2020 in Review

Capital Counsel sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2020, closing a stake of 3 shares — an estimated $9K sold.

Capital Counsel first reported a position in SEEL in Q3 2020 and held it in 1 quarter. The position peaked at $9K in Q3 2020. 26 funds tracked by Wall St. Rank hold SEEL as of Q4 2020.

  • Capital Counsel reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Capital Counsel sold 3 Seelos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $9K.
  • Capital Counsel first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Capital Counsel's Seelos Therapeutics, Inc. Common Stock position peaked at $9K in Q3 2020.
  • 26 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Capital Counsel's 13F filing for Q4 2020, filed 10 Feb 2021.